Incidence of late clonal complications in patients with acquired AA treated with immunosuppression
| Reference (year) . | Study design . | Patients, n . | Age, median (range), y . | Follow-up, median, y . | Patients with PNH, n . | Projected incidence of PNH, % (follow-up, y) . | Patients with secondary MDS/AML, n . | Projected incidence of MDS/AML, % (follow-up, y) . |
|---|---|---|---|---|---|---|---|---|
| 26 (1989) | Retrospective: EBMT registry analysis of late survivors post-IST (survived > 2 y) | 223 | 23 (1-73) | 4 | 19 | 13 (7) | 12 | 15 (7) |
| 28 (2011) | Prospective: IST, with or without G-CSF | 192 | 46 (2-81) | 6 | 37 | 19 (6) | 6 | 4 (6) |
| 27 (1988) | Prospective: ALG + androgen | 103 | 20 (8-52)* | 3 | 13 | ∼31 (10) | 9 | 26 (10) |
| 29 (2003) | Prospective: ATG + CsA | 122 | 35 (N/A) | 7 | 7 | 10 (7) | N/A | N/A |
| 30 (2011) | Retrospective: varied, including G-CSF, CsA, ATG, androgens | 802 | 23 (3-71) | 6 | 21 | 1.7 (5) | 19 | 2.1 (5) |
| 31 (2002) | Prospective: ALG + CsA + danazol, with or without G-CSF | 113 | 9 (1-18) | 8 | N/A | N/A | 12 | 13.7 (8) |
| 32 (2003) | Prospective: ATG, with or without CsA | 94 | 32 (2-80) | 11 | 5 | 10 (11) | 4 | 8 (11) |
| 33 (1993) | Retrospective: EBMT registry analysis, various IST regimens | 860 | 29 (3-83)† | 3 | N/A | N/A | 43 | 16.6 (10) |
| 34 (2017) | Prospective: ATG + CsA + eltrombopag | 92 | 32 (3-82) | 2 | 2 | N/A | 5 | N/A, <8 (2) |
| Reference (year) . | Study design . | Patients, n . | Age, median (range), y . | Follow-up, median, y . | Patients with PNH, n . | Projected incidence of PNH, % (follow-up, y) . | Patients with secondary MDS/AML, n . | Projected incidence of MDS/AML, % (follow-up, y) . |
|---|---|---|---|---|---|---|---|---|
| 26 (1989) | Retrospective: EBMT registry analysis of late survivors post-IST (survived > 2 y) | 223 | 23 (1-73) | 4 | 19 | 13 (7) | 12 | 15 (7) |
| 28 (2011) | Prospective: IST, with or without G-CSF | 192 | 46 (2-81) | 6 | 37 | 19 (6) | 6 | 4 (6) |
| 27 (1988) | Prospective: ALG + androgen | 103 | 20 (8-52)* | 3 | 13 | ∼31 (10) | 9 | 26 (10) |
| 29 (2003) | Prospective: ATG + CsA | 122 | 35 (N/A) | 7 | 7 | 10 (7) | N/A | N/A |
| 30 (2011) | Retrospective: varied, including G-CSF, CsA, ATG, androgens | 802 | 23 (3-71) | 6 | 21 | 1.7 (5) | 19 | 2.1 (5) |
| 31 (2002) | Prospective: ALG + CsA + danazol, with or without G-CSF | 113 | 9 (1-18) | 8 | N/A | N/A | 12 | 13.7 (8) |
| 32 (2003) | Prospective: ATG, with or without CsA | 94 | 32 (2-80) | 11 | 5 | 10 (11) | 4 | 8 (11) |
| 33 (1993) | Retrospective: EBMT registry analysis, various IST regimens | 860 | 29 (3-83)† | 3 | N/A | N/A | 43 | 16.6 (10) |
| 34 (2017) | Prospective: ATG + CsA + eltrombopag | 92 | 32 (3-82) | 2 | 2 | N/A | 5 | N/A, <8 (2) |
ALG, antilymphocyte globulin; ATG, anti-thymocyte globulin; CsA, cyclosporine A; EBMT, European Cooperative Group for Bone Marrow Transplantation; G-CSF, granulocyte colony-stimulating factor; IST, immunosuppressive therapy; N/A, not available.
Mean age.
Age corresponds to patients with MDS/AML evolution.